ArticleFrontiers in oncology2026
Reduced Nectin-4 expression in lymph node metastases of penile squamous cell carcinoma: a paired primary-metastatic analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate Nectin-4 expression in primary and matched metastatic penile squamous cell carcinoma (PSCC) lesions and to assess its associations with clinicopathological features and survival outcomes. Methods: We analyzed 123 patients with pathologically confirmed PSCC treated at our hospital between 2018 and 2024. Nectin-4 expression was assessed by immunohistochemistry using the H-score (0-300) in primary tumors and 30 matched lymph node metastases, and associations with pathological features, paired primary-metastatic differences, and survival outcomes were analyzed. Results: Nectin-4 was widely expressed in PSCC. Higher Nectin-4 expression was observed in less aggressive tumors. Expression was higher in T1 than in T2 stage (95% CI 19.10-79.28; P < 0.01) and decreased from G1 to G3, with significant differences between G1 and G2 (95% CI 0.39-63.83; P = 0.047) and between G1 and G3 (95% CI 24.41-170.43; P = 0.009). Expression in primary tumors was not significantly associated with nodal status. In paired samples, lymph node metastases showed lower H-scores than their matched primary tumors (95% CI 3.52-72.82; P = 0.032). Low Nectin-4 expression was associated with shorter overall survival in Kaplan-Meier and univariable Cox analyses, but it was not independently associated with survival after multivariable adjustment. Conclusions: Nectin-4 expression in PSCC is higher in early, better-differentiated tumors and lower in lymph node metastases. Low Nectin-4 expression was associated with poorer overall survival, although it was not an independent prognostic factor. These findings suggest that Nectin-4 may have prognostic relevance and potential value as a therapeutic target in PSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.